Sex differences in CMV Replication and HIV Persistence during Suppressive ART

Sara Gianella¹, Sarah McDonald Tran¹, Sheldon Morris¹, Millie Vargas¹, Magali Porrachia¹, Michelli F. Oliveira¹, Steve Lada¹, Mitchell Zhao¹, Grant B. Ellsworth³, Jyoti S. Mathad³, Timothy Wilkin³

¹University of California, San Diego, La Jolla, CA, USA,
³Weill Cornell Medicine, New York, USA

Corresponding:
#Sara Gianella, MD
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California San Diego
9500 Gilman Drive MC 0679,
La Jolla, CA 92093-0679, USA
E-mail: gianella@ucsd.edu

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

Background

The association between subclinical CMV replication and HIV persistence has not been investigated in cis-gender women with HIV.

Methods

Fifty virologically suppressed female participants with HIV were prospectively enrolled and provided oral, vaginal, urine samples and peripheral blood mononuclear cells (PBMCs) at one cross-sectional time-point. Cytomegalovirus (CMV) DNA was quantified in each specimen by real-time PCR. Cellular HIV DNA and HIV RNA transcripts (unspliced and multiply spliced [ms] encoding tat-rev) were quantified by droplet digital (dd)PCR. Historical data from 49 male individuals with HIV and CMV were used as controls.

Results

Levels of cellular HIV DNA and unspliced HIV RNA were not different between sexes, but female participants had less detectable msHIV RNA and CMV DNA compared to males (both P<0.01). Unlike previously described for males, the presence of CMV DNA was not associated with increased HIV DNA in females. Among female participants, pre-menopausal status was independently associated with lower HIV DNA compared to post-menopause, after adjusting for nadir CD4 count (P<0.01).
Conclusions.

Female participants with HIV have reduced cellular HIV RNA and less subclinical CMV DNA compared to males, but overall similar HIV DNA levels in our study. Post-menopausal status was independently associated with higher HIV DNA levels among female participants.
**Introduction**

Antiretroviral therapy (ART) improves health, prolongs survival and reduces HIV transmission [1]. Nevertheless, HIV infection remains associated with morbidity and mortality due to non-AIDS defining events [1-3]. Increased morbidity and mortality are associated with inflammation and immune dysfunction, which persists in some people with HIV on suppressive ART [2]. Potential contributors to inflammation include direct effect of low level HIV replication, translocation of bacterial/fungal products from the gut into the systemic circulation, and viral co-infections such as cytomegalovirus (CMV) [14-18]. Further, CMV-driven inflammation might modulate and maintain the HIV reservoir through various mechanisms in the setting of suppressive ART [3].

Our group has investigated extensively the connections between CMV replication, systemic immune activation and levels of HIV DNA in men who have sex with men (MSM) with HIV in Southern California. We reported that subclinical CMV reactivation in seminal plasma and detectable CMV DNA in peripheral blood cells were associated with T-cell dysfunction, and also with higher levels of HIV DNA [4-6]. These findings support clinical trials of anti-CMV drugs or vaccines to decrease systemic immune activation, to prevent end-organ diseases and reduce the latent HIV DNA reservoir. However, female participants cannot be included in these trials without optimizing detection of CMV reactivation and investigating if CMV reactivation in females might induce the same immunologic and virologic outcomes as observed in males. Only sparse data exist regarding asymptomatic CMV shedding in females with HIV, including the following: Two studies in the U.S. including cis-gender women with HIV with partial uptake of ART found that CMV DNA was detected infrequently in cervicovaginal lavage (CVL) with 55/764 (7%) and 10/312 (3%) positive samples [7, 8]. Two studies in Sub-Saharan Africa, reported significantly higher levels of CMV detectability between 59-78% of provider collected cervical swab samples [9, 10]. These data demonstrate the variability of CMV shedding and the regional
differences but also the sparse data available about CMV shedding from mucosal sites in females on suppressive ART. Here, we prospectively enrolled 50 virologically suppressed cis-gender women with HIV in New York City to collect oral, vaginal, urine samples and peripheral blood mononuclear cells (PBMCs) at one time-point. We quantified CMV DNA in each specimen as well as cellular HIV DNA and HIV RNA transcripts in peripheral blood mononuclear cells (PBMC). Historical data from 49 MSM were used as controls. Our primary goal was (i) to describe the burden of CMV among women with HIV and (ii) to investigate if presence of CMV DNA (among other factors) was associated with levels of HIV DNA in female participants.

Methods

Cohort and Samples.
Fifty virologically suppressed cis-gender women with HIV were prospectively enrolled in New York City at Weill Cornell Medicine between July 2014 and September 2016. Participants provided genital samples (self-collected vaginal swabs N=50, provider collected cervical swabs N=14 and cervicovaginal lavage (CVL) N=14), oral samples (rinses N=50, swabs N=42), peripheral blood mononuclear cells (PBMCs, N=50) and urine (N=50) at one cross-sectional time-point. As controls, we used historical data from cis-gender MSM with HIV and CMV enrolled in the California Collaborative Treatment Group (CCTG) 592 [11]. Briefly, CCTG 592 is a study of an internet-based behavioral intervention of sexually active MSM that included baseline collection of semen and a longitudinal follow up on a total 180 MSM with HIV that could be on or off ART. For this study, we included a baseline data from subset of 49 cis-gender men who were receiving effective ART with blood plasma HIV RNA <50 copies/ml within three months before the seminal sample collection.
The studies were conducted with appropriate written subject consent and were approved by the Human Research Protections Program at the University of California, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, the University of Southern California, and Weill Cornell Medicine.

**CMV Quantification in Genital Secretion, Oral secretion and Urine**

For oral rinse and CVL, the volumes of supernatants were measured (20-30mL mouthwash, 8-11mL CVL) and ultra-centrifuged at 23,500 x g, 4°C for 1 hour. 200µl supernatant was used to isolate DNA following QIAamp DNA Mini Kit’s (Qiagen, USA) protocol. Cellular pellets (obtained from CVL and oral rinse) directly underwent DNA extraction using the same QIAamp DNA Mini kit. Further, 500µl of eluted DNA per sample was concentrated via standard ethanol DNA precipitation protocol.

Urine was pelleted by high-speed centrifugation at 23, 500 x g 4C for 1 hour. 140µl of concentrate was used to isolate DNA using QIAamp Viral RNA Mini Kit (Qiagen, USA) per manufacture’s protocol.

For dry oral, vaginal and cervical swabs, DNA was extracted by re-suspending the swab in 400µl 1X Dulbecco’s Phosphate-Buffered Saline (DPBS). The entire 400µl suspension of each swab sample was collected by using autoclave-able assemblies of spin-baskets (Kerafast, USA) and 1.5ml Eppendorf snap-cap microcentrifuge safe-lock tubes (Fisher Scientific, USA), after centrifugation at >10, 000 x g, 23C for 1 minute[4]. DNA was extracted from the total 400µl suspension with the QIAamp DNA Mini Kit. Ethanol-based DNA precipitation was performed to concentrate the DNA. For semen, DNA was extracted as previously described [4, 6].
CMV was measured from all extracted and precipitated DNA by real-time PCR using known CMV plasmid concentrations as standard curve on Applied Biosystems’ 7500 Real Time PCR Systems (Thermo Fisher Scientific, USA) [12].

**Cellular HIV DNA and CMV DNA in PBMC.**

DNA was extracted from 5 million PBMC for each time-point using AllPrep DNA/RNA Mini Kit (Qiagen, CA). Total HIV DNA (pol) and 2-LTR junction were quantified by droplet digital PCR (ddPCR) from extracted DNA as previously described [13]. Copy numbers were calculated as the mean of replicate PCR measurements and normalized to one million CD4\(^+\) T cells as determined by RPP30 (total cell count) and flow cytometry (percentage of CD4\(^+\) T cells) [14].

**Cellular HIV RNA in PBMC**

Cellular HIV RNA was extracted from PBMC using the AllPrep DNA/RNA Mini Kit (Qiagen, CA) following the manufacturer’s protocol with addition of a DNase step to avoid DNA contamination (RNase-free DNase Set, Qiagen, CA). Extracted RNA (500ng) was reverse transcribed into 20\(\mu\)L cDNA (iScript Advanced cDNA Synthesis Kit for RT-qPCR, Bio-Rad) using the manufacturer's protocol. The cDNA product (approximately 300ng) was added to the ddPCR reaction. Unspliced (us)HIV RNA (Gag) and multiply-spliced (ms)HIV RNA (TatRev) PCRs were performed as a duplex with HEX (usGag) and FAM (msTatRev) probes respectively, using primers and probes as previously described [15, 16]. Copy numbers were calculated as the mean of replicate PCR measurements, and normalized to total RNA as determined by A260/A280 absorptivity ratio using a NanoDrop 2000 spectrophotometer (Thermo Scientific) [4].
Anti-CMV IgG antibody levels

Anti-CMV IgG antibody levels were measured in blood plasma. Units per mL (U/mL) were determined by interpolation from a standard curve of a known anti-CMV IgG solution, as previously described [17, 18].

Sex hormones levels

Levels of Estradiol, Progesterone and Follicle-stimulating hormone (FSH) were measured using the Estradiol ELISA kit (Ref EIA-2693, DRG International, Inc.), Progesterone ELISA kit (Ref EIA-1561, DRG International, Inc.) and FSH ELISA kit (Ref EIA-1288, DRG International, Inc.) following manufactures’ protocols.

Statistical Analysis

We used descriptive statistics to characterize the study populations. We used Fisher’s exact test to compare dichotomous variables between groups, and Kruskal-Wallis tests to compare continuous variables between groups. We examined predictors of HIV DNA using generalized linear models. To build the multivariable models, we included all variables with a P-Value <0.15 in the univariable analysis. Then, we removed variables with a P-Value >0.15 in a stepwise fashion to build the final model. Continuous variables were log transformed as needed to normalize the distribution. All statistical analyses were performed using SAS Version 9.4.
Results

Cohort and Samples

For female participants, median age was 53 years; 26 (52%) were post-menopausal (self-reported); and 43 (86%) acquired HIV through heterosexual contact. Median time on suppressive ART was 7.8 years (IQR: 4.2-13.1). Median current CD4+ T cell count was 721 cells/μl (IQR: 490-930) and Nadir CD4+ was 172 cells/μl (IQR: 56-265). For clinical details and comparison with the male participants, see Table 1. Importantly, the two groups were significantly different by ethnicity/race, mode of HIV transmission, age, and current CD4 T cell count. For hormonal levels in women by menopausal status, see Supplementary Table 1.

Differences in CMV Replication and HIV Persistence among Women and Men

One woman was CMV IgG negative. Of the 49 female participants with both HIV and CMV, 15/49 (29%) had detectable CMV DNA in at least one specimen type (Figure 1), most frequently self-collected vaginal swabs (8/49, 16%) and PBMCs (7/48, 15%), followed by oral rinse (combined supernatant and pellet, 4/49, 8%), oral swabs (1/39, 2.6%), CVL and urine (both 0%). Detectability was often inconsistent across sampled location. As a comparison, of the 49 cis-gender men with HIV and CMV, 26/49 (53%) had detectable CMV DNA in at least one specimen type, most frequently in semen (40%) and in PBMC (21%). Overall, male participants had significantly more detectable CMV replication than females (Fisher P<0.01). We also obtained quantitative CMV DNA levels. Specifically, CMV DNA in PBMC ranged 3-18 copies/10^6 cells in females and 2-59 in males (P>0.2); CMV DNA in vaginal swab ranged 7-40 copies/ml elution, seminal CMV DNA 220-26,671 copies/ml seminal plasma (P<0.001); CMV in oral mucosa ranged 6-12,744 copies/ml elution for females, data on oral mucosa were not available for men.
Levels of cellular HIV DNA and unspliced HIV RNA were not different between sexes, but female participants were less likely to have detectable msHIV RNA (54% versus 100% in cis-gender men, Fisher P<0.001).

**Associations between CMV DNA, HIV Reservoir Measures and other Variables in women**

Unlike our previous findings in males [6, 19], CMV DNA (overall and at any sampled location) had no effect on any measure of HIV persistence in female participants (P>0.2). There was also no difference in cellular HIV RNA transcription and CMV shedding between pre- and post-menopausal women.

Among female participants, pre-menopausal status was associated with significantly lower HIV DNA compared to post-menopause (42 versus 150 HIV DNA copies/10^6 cells, P<0.01. Males: 90 copies/10^6 cells, **Figure 2**). Overall among female participants, higher HIV DNA concentrations were associated with lower nadir CD4 counts, higher FSH concentrations, older age and post-menopausal status. In the multivariable model, lower nadir CD4 counts and post-menopausal status remained independently associated with higher HIV DNA concentrations.

When evaluating concentrations of sex hormones, we did not find any effect of estradiol or progesterone on HIV RNA transcription or HIV DNA levels. However, we did observe a positive correlation between FSH and HIV DNA (P<0.01, **Figure 3**). In the multivariable model, FSH was not independently correlation with HIV DNA when accounting for menopausal status.
**Discussion**

If we are to cure HIV, we must understand the mechanisms that allow the HIV DNA reservoir to persist despite ART. We have previously shown that asymptomatic CMV reactivation in MSM is associated with higher levels of HIV DNA and with increased systemic immune activation and proliferation of CD4+ T-cells. This was observed in male participants both receiving and not receiving antiretroviral therapy [4, 6]. It remains unclear, however, if CMV reactivation in females induces the same immunologic and virologic consequences. Additionally, while CMV is most reliably detected in the male genital tract, the optimal location or strategy for detecting CMV replication in women is unclear.

Overall, our study found that female participants have significantly less detectable CMV DNA compared to males (Fisher P<0.01), even if sampled in more mucosal sites (i.e. genital, urine, oral and PBMC for females compared to seminal plasma and PBMC for males). For females, CMV DNA was most frequently detected in self-collected vaginal swabs (16%) and PBMCs (15%), followed by oral rinse (8%), oral swabs (3%), CVL and urine (both 0%). These data are similar to previous reports in the U.S. [7, 8], but lower than data reported from Sub-Saharan Africa [9, 10]. When comparing the genital compartment, females had significantly lower levels of CMV DNA (average: 15 copies/ml versus 7,600 copies/ml, P<0.001) compared to males. On the other hand, the detection of CMV DNA in PBMC was similar between males and females, (21% and 15%, respectively). The presence of CMV DNA in blood cells (usually monocytes) may reflect low level viral replication but may also simply reflect latent CMV infection and not necessarily CMV replication.

Regarding measures of HIV persistence, levels of cellular HIV DNA and unspliced HIV RNA were not different between sexes, but female participants were less likely to have detectable msHIV RNA (54% versus 100% in cis-gender men, Fisher <0.01). This is in line with a previous study from Scully et al [20], that showed higher cell-associated HIV RNA, higher plasma HIV-1
(single copy assay), and higher T-cell activation and PD-1 expression in females compared to males, but this previous study did not evaluate CMV persistence.

Subsequently, we assessed the effect of CMV and other clinical variables on the HIV reservoir among female participants. Unlike our previous findings in males [6, 19], CMV had no effect on any measure of HIV persistence in females. Among the other variables, pre-menopausal status was associated with significantly lower HIV DNA compared to post-menopause, even after adjusting for age and duration of suppression on ART (P<0.01). In line with these findings, higher levels of FSH were associated with higher HIV DNA. One possible mechanism is in vivo exposure to estrogen which has been shown to repress HIV transcription in latency models and patient cells [21] as well as in vitro infection systems [22], indicating a direct role for hormones in mediating sex differences.

This study had several limitations. First the limited sample size and the cross-sectional study design likely limit our capacity to observe some associations. Specifically, a single time point does not adequately capture participants with CMV DNA because of the intermitted nature of the viral shedding. This results in the potential for misclassification which would affect the ability to detect an effect. Also, the study populations were different and recruited at different sites (New York versus Southern California) which might introduce some selection bias. There was a notable difference in race/ethnicity between the two cohorts with a majority of Black females compared to white males. It is important to note that the seroprevalence of CMV was similar in both cohorts and a difference in CMV shedding by race/ethnicity is currently not known. Our data from the the U.S. are likely not generalizable to the population of females with HIV worldwide.

Further, while we were not able to observe a direct effect of estradiol on any marker of HIV persistence at single time-points, we did not measure expression of estrogen receptor as part of our study. Also, the age range of the women was relatively narrow which might explain the lack
of association between estradiol and any marker of HIV persistence. A longitudinal approach should better address the impact of the contemporaneous hormone levels on virus activity.

Nevertheless, this study provides key information regarding the pattern of CMV shedding in females, as compared to males. Specifically, the male genital tract constitutes a concentrated reservoir of CMV DNA replication which likely alters the local and systemic immunologic and viral dynamics [3, 23, 24]. For females in our U.S. study, CMV shedding is much less frequent with inconsistent detection at various locations with significantly lower viral loads. While we were not able to observe an effect of CMV shedding on HIV persistence in our study, the systemic immunologic effect of CMV shedding in females needs further elucidation. Also, the optimal sampling strategy to measure CMV shedding in female likely requires a combination of oral and genital swabs.

Our study also provides some interesting insights into the association between menopausal status and HIV persistence. Overall, our observations provide further evidence that virologic outcomes after curative interventions may differ by sex and by menopausal status, requiring careful attention to enrolling an adequate number of women of all ages in cure studies and to reporting sex-delineated outcomes.
Table 1: Sex differences in Demographics.

| Demographics                  | Women (N=50) | Men (N=49) | P-values |
|-------------------------------|--------------|------------|----------|
| **Ethnicity, n (%)**          |              |            |          |
| Hispanic                      | 7 (14%)      | 19 (39%)   | P<0.001  |
| Non-Hispanic                  | 43 (86%)     | 30 (61%)   |          |
| **Race, n (%)**               |              |            |          |
| Asian                         | 1 (2%)       | 2 (4%)     | P<0.001  |
| Black                         | 37 (74%)     | 11 (22%)   |          |
| Native-American               | 1 (2%)       | 0          |          |
| Other                         | 3 (6%)       | 0          |          |
| White                         | 8 (16%)      | 36 (74%)   |          |
| **HIV transmission, n (%)**   |              |            |          |
| IDU                           | 3 (6%)       | 0          | P<0.001  |
| Sex with men                  | 43 (86%)     | 48 (98%)   |          |
| Both                          | 2 (4%)       | 0          |          |
| Other                         | 2 (4%)       | 1 (2%)     |          |
| **Menopausal status, n (%)**  |              |            |          |
| Pre-menopausal                | 24 (48%)     | NA         |          |
| Post-menopausal               | 26 (52%)     | NA         |          |
| **Age (years), median (IQR)** |              |            |          |
|                              | 53 (47-57)   | 46 (38-51) | P<0.01   |
| **Current CD4⁺ cells (cells/mm³), median (IQR)** | 721 (490-930) | 625 (538-774) | P=0.04 |
| **Nadir CD4⁺ cells (cells/mm³), median (IQR)** | 172 [56-265] | 215 (68-350) | P=0.12 |

**Legend:** n (%): number (percent), IQR: inter quartile range, IDU: Injection drug users, NA: Not available
Table 2: Sex differences in CMV and HIV Reservoir data

|                      | Women (N=50) | Men (N=49) | P-values |
|----------------------|--------------|------------|----------|
| **CMV Data**         |              |            |          |
| CMV IgG seropositive, n (%) | 49 (98%)    | 48 (98%)   | P>0.2    |
| CMV IgG levels, UI/ml median (IQR) | 37 (33-41)  | 34 (26-43) | P>0.2    |
| Detectable CMV DNA (any samples), n (%) | 15 (29%)    | 26 (53%)   | P<0.01   |
| **HIV Reservoir Data** |              |            |          |
| HIV DNA levels (copies/10⁶ cells), median (IQR) | 89 (19-209) | 90 (18-148) | P>0.2 |
| Unspliced cellular HIV RNA levels (per 200ng DNA Input), median (IQR) | 7 (3-15) | 7 (4-15) | P>0.2 |
| Detectable multiply spliced cellular HIV RNA, n (%) | 27 (54%) | 41 (100%)* | P<0.001 |

**Legend:** n (%): number (percent), IQR: inter quartile range, CMV: cytomegalovirus. * Cellular HIV RNA data for men only available on a subset of n=41.
Table 3. Predictors of HIV DNA (copies/10^6 PBMC) in Women

| Factor                              | Univariable (β, p-value) | Multivariable (β, p-value) |
|-------------------------------------|--------------------------|---------------------------|
| Current CD4 (per 100 cell/mm3)      | -8*, 0.43                |                           |
| Current CD4% (per %)                | -0.97, 0.71              |                           |
| Nadir CD4 (per 100 cells/mm3)       | -36, 0.02                | -43, <0.01                |
| Time on ART (per 10 years)          | -55, 0.26                |                           |
| Low level viremia (yes vs. no)      | -15, 0.84                |                           |
| CMV Detected (yes vs. no)           | 54, 0.31                 |                           |
| Menopause (post-menopausal vs. per menopausal) | 123, <0.01 | 144, <0.01 |
| Age (per 10 years)                  | 77, <0.01                |                           |
Figure Legend.

**Figure 1.** CMV Shedding pattern among 15 women with detectable CMV DNA in at least one sampled site

**Figure 2.** Levels of total HIV DNA in men, pre-menopausal (pre-M) and post-menopausal (post-M) women. **P-value<0.001, *P<0.05

**Figure 3.** Regression analysis between FSH and total HIV DNA in pre and post-menopausal group (continuous and dotted lines respectively).
Acknowledgments / Funding

This work was supported by the Department of Veterans Affairs and grants from the National Institutes of Health: AI68636, AI-68634 (ACTG-supplements), AI036214 (Smith-CFAR), MH062512 (Heaton-HNRC), AI134295 (Gianella-Sex Hormones & Persistence), HD094646 (Gianella-Declining Sex Hormones), AI120009 (R01 Smith-P3 deep sequencing tech), AI131385 (P01 Smith-R3 Last Gift, Early Treatment interruption), AI100665 (Smith-K24Training), MH097520 (Smith-Viral Aging), DA034978 (Smith-Avant Garde), DA041007 (Smith-SMRT Brain TaPHR), AI118422 (Smith-Perturb Immune Stimulation), MH107345 (Heaton/Letendre-HAND-Age-related), AI106039 (Little-PIRC), AI027763 (Gianella Supplement-CMV driven mechanisms). The following grants also contributed support: AG044325 (Gianella-WakeForest), ID15-SD-063 (Gianella-CHRP); The James B. Pendleton Charitable Trust; the California HIV/AIDS Research Program (CHRP) HD15-SD-059 and PR15-SD-021. Conselho Nacional de Desenvolvimento Científico eTecnológico (CNPq)-Brazil (to M.F.O)

Conflicts of Interest

Authors have not Conflicts of Interest.
References.

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-33.
2. Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. Current opinion in immunology 2012; 24:501-6.
3. Christensen-Quick A, Vanpouille C, Lisco A, Gianella S. Cytomegalovirus and HIV Persistence: Pouring Gas on the Fire. AIDS Res Hum Retroviruses 2017; 33:S23-S30.
4. Gianella S, Massanella M, Richman DD, et al. Cytomegalovirus Replication in Semen is Associated with Higher Levels of Proviral HIV DNA and CD4+ T cell Activation during Antiretroviral Treatment. J Virol 2014; 88:7818-27.
5. Christensen-Quick A, Massanella M, Frick A, et al. Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy. Journal of Virology 2019; 93:e00179-19.
6. Gianella S, Anderson CM, Var SR, et al. Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol 2016; 90:3944-52.
7. Schoenfisch AL, Dollard SC, Amin M, et al. Cytomegalovirus (CMV) shedding is highly correlated with markers of immunosuppression in CMV-seropositive women. Journal of medical microbiology 2011; 60:768-74.
8. Mitchell C, Hitti J, Paul K, et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses 2011; 27:35-9.
9. Mostad SB, Kreiss JK, Ryncarz AJ, et al. Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. J Med Virol 1999; 59:469-73.
10. Gianella S, Redd AD, Grabowski MK, et al. Vaginal Cytomegalovirus Shedding Before and After Initiation of Antiretroviral Therapy in Rakai, Uganda. J Infect Dis 2015; 212:899-903.
11. Gianella S, Smith DM, Vargas MV, et al. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1 infected men who have sex with men. Clin Infect Dis 2013; In press.
12. Centers for Disease Control and Prevention. HIV Surveillance Report v. http://www.cdc.gov/nchhstp/newsroom/docs/2012/stages-of-carefactsheet-508pdf, published July 2012, accessed August 2013.
13. Strain MC, Lada SM, Luong T, et al. Highly Precise Measurement of HIV DNA by Droplet Digital PCR. PLoS One 2013; 8:e55943.
14. Massanella M, Gianella S, Lada SM, Richman DD, Strain MC. Quantification of Total and 2-LTR (Long terminal repeat) HIV DNA, HIV RNA and Herpesvirus DNA in PBMCs. Bio Protoc 2015.
15. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32:292-300.
16. Schmid A, Gianella S, von Wyl V, et al. Profound Depletion of HIV-1 Transcriptionally Active PBMC by Early cART during Primary HIV-1 Infection but Not by Treatment during Chronic Infection: Results of the Zurich Primary HIV Infection Study. PLoS One 2010; 5:e13310.
17. Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. The Journal of infectious diseases 2012; 205:1788-96.
18. Gianella S, Morris SR, Tatro E, et al. Virologic Correlates of Anti-CMV IgG Levels in HIV-1 Infected Men. J Infect Dis 2014; 209:452-6.
19. Gianella S, Massanella M, Wertheim JO, Smith DM. The Sordid Affair between Human Herpesvirus and Human Immunodeficiency Virus J Infect Dis 2015; 212:845-52.
20. Scully EP, Gandhi M, Johnston R, et al. Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. The Journal of infectious diseases 2018; 219:1084-94.
21. Das B, Dobrowolski C, Luttge B, et al. Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences 2018; 115:E7795-E804.
22. Szotek EL, Narasipura SD, Al-Harthi L. 17beta-Estradiol inhibits HIV-1 by inducing a complex formation between beta-catenin and estrogen receptor alpha on the HIV promoter to suppress HIV transcription. Virology 2013; 443:375-83.
23. Freeman ML, Lederman MM, Gianella S. Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection. Curr HIV/AIDS Rep 2016; 13:10-9.
24. Gianella S, Letendre S. CMV and HIV: A Dangerous “Pas de Deux”. J Infect Dis 2016.
Figure 1

Total HIV DNA levels

Men
Pre-M Women
Post-M Women
| Obs | Vag Swab | Oral Swab | Oral Pellet | Oral Sup | PBMC |
|-----|---------|-----------|-------------|----------|------|
| 1   |         |           |             |          |      |
| 2   |         |           |             |          |      |
| 3   |         |           |             |          |      |
| 4   |         |           |             |          |      |
| 5   |         |           |             |          |      |
| 6   |         |           |             |          |      |
| 7   |         |           |             |          |      |
| 8   |         |           |             |          |      |
| 9   |         |           |             |          |      |
| 10  |         |           |             |          |      |
| 11  |         |           |             |          |      |
| 12  |         |           |             |          |      |
| 13  |         |           |             |          |      |
| 14  |         |           |             |          |      |
| 15  |         |           |             |          |      |
Figure 3

[Graph showing data points and lines representing FSH (mIU/mL) against HIV DNA (copies/ml) across different stages of menopause: overall, post-menopause, pre-menopause.]